Literature DB >> 27062882

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Patrick A Flume.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27062882     DOI： 10.1016/S1569-1993(16)00018-7

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN： 1569-1993            Impact factor:   5.482


× No keyword cloud information.
  7 in total

1.  β-Lactam Combinations That Exhibit Synergy against Mycobacteroides abscessus Clinical Isolates.

Authors:  Elizabeth Story-Roller; Christos Galanis; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

2.  Synergistic Efficacy of β-Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Select β-Lactam Combinations Exhibit Synergy against Mycobacterium abscessus In Vitro.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

4.  Activities of Dual Combinations of Antibiotics Against Multidrug-Resistant Nontuberculous Mycobacteria Recovered from Patients with Cystic Fibrosis.

Authors:  Matthew Schwartz; Stefanie Fisher; Elizabeth Story-Roller; Gyanu Lamichhane; Nicole Parrish
Journal:  Microb Drug Resist       Date:  2018-01-25       Impact factor: 3.431

5.  T405, a New Penem, Exhibits In Vivo Efficacy against M. abscessus and Synergy with β-Lactams Imipenem and Cefditoren.

Authors:  Binayak Rimal; Hunter R Batchelder; Elizabeth Story-Roller; Chandra M Panthi; Chavis Tabor; Eric L Nuermberger; Craig A Townsend; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2022-05-31       Impact factor: 5.938

Review 6.  Mycobacterium abscessus and β-Lactams: Emerging Insights and Potential Opportunities.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Keira A Cohen; Gyanu Lamichhane
Journal:  Front Microbiol       Date:  2018-09-25       Impact factor: 5.640

7.  Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection.

Authors:  Emily C Maggioncalda; Elizabeth Story-Roller; Danielle A Nicklas; Benjamin Eichelman; Chavis Tabor; Alisa W Serio; Tiffany R Keepers; Surya Chitra; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.